Rochester, MN Clinical Trials Report — May 2026

For patients and healthy volunteers in Rochester, MN, May 2026 brings both urgent opportunities to participate in clinical research and exciting new studies. With 69 trials slated to close their enrollment within the next 90 days, prompt action is essential for those interested in contributing to medical advancements.

Among these rapidly closing studies, 11 are still actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition. This is a significant opportunity for individuals looking to participate before these windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also have limited time to join research. Trials focused on various conditions are nearing their enrollment deadlines. Conditions with trials closing soon include:

• Healthy (3 trials)
• Ulcerative colitis (3 trials)
• Gastroesophageal cancer (2 trials)
• Osteoarthritis, knee (2 trials)
• Obesity (2 trials)
• Alzheimer disease (1 trial)
• Alzheimer dementia (1 trial)
• Advanced breast cancer (1 trial)
• Anatomic stage iii breast cancer ajcc v8 (1 trial)
• Anatomic stage ii breast cancer ajcc v8 (1 trial)

New Research Opportunities Emerge in Rochester

This month, Rochester, MN, saw the opening of 16 new clinical trials, an increase from the 13 trials that launched in April 2026. This brings the total number of actively recruiting clinical trials in Rochester, MN, to 1,120 across 130 research facilities, highlighting the city's robust research landscape.

May brings several notable new trials to Rochester, MN, including significant studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Eli Lilly and Company is sponsoring a notable Phase 2 study, NCT07589595, "A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)." This trial aims for 350 participants to evaluate whether treatment with donanemab slows the progression of cognitive and functional decline in individuals with early cognitive decline.
• The Mayo Clinic is initiating NCT07572955, "A Study Of Acute Decompensated Heart Failure." This study involves 500 participants and seeks to examine shorter hospitalization length and reduced rates of recurrent heart failure hospitalization compared to current standard of care in Acute Decompensated Heart Failure.
• Also from the Mayo Clinic, NCT07570940, "A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery," is a Phase 4 study with 450 participants. It assesses the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients receiving pre-surgical stellate ganglion blockade.
• Matthias Stuber is sponsoring NCT07613398, "An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function." This project involves 300 participants and aims to evaluate a new cardiac MRI technique, the Free-Running Framework (FRF), to simplify and accelerate cardiac image acquisition.
• Duke University is leading NCT07567794, "GBPDC: Gut-Brain in PD Consortium Master Protocol." This study, with 250 participants, aims to identify the role that the gut-brain axis plays in Parkinson's disease (PD). The National Institute of Diabetes and Digestive and Kidney Diseases is sponsoring this research.
• The Mayo Clinic is also conducting NCT07612007, "HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization." This Phase 2b trial, with 80 participants, tests the effect of HRX215 in treating patients with colorectal cancer that has spread to the liver after undergoing a portal vein embolization.

New trials this month are exploring a range of conditions, with new studies focusing on acute decompensated heart failure, amyloid, anterior cruciate ligament injuries, atrial fibrillation, cardiac diseases, and cardiac sarcoidosis. Drug trials account for the largest share of new studies, with 7 new drug trials, followed by 3 procedure trials and 3 other types of studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research in Rochester, MN. Of the 16 new trials launched this month, 1 is actively seeking healthy volunteers. Across Rochester, a total of 124 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Rochester's Leading Research Facilities

Rochester, MN, is dominated by the Mayo Clinic system, which consistently runs a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Mayo Clinic (424 trials)
• Mayo Clinic in Rochester (350 trials)
• Mayo Clinic Rochester (79 trials)
• Mayo Clinic - Rochester (35 trials)
• Research Site (31 trials)
• Mayo Clinic Minnesota (21 trials)
• Mayo Clinic, Rochester (12 trials)
• Mayo Clinic in Rochester, Minnesota (11 trials)
• Mayo Clinic in Minnesota (5 trials)
• Mayo Clinic Cancer Center (5 trials)
• Clinical Trial Site (5 trials)
• Mayo Clinic - PIN (4 trials)

These institutions, primarily under the Mayo Clinic umbrella, offer a broad spectrum of research, from oncology at the Mayo Clinic Cancer Center to diverse medical fields across their various Rochester locations.

Broadening Your Search: Nearby Options

While Rochester, MN, offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Minnesota. Cities with active trials include Minneapolis (15 trials), Dilworth (1 trial), Golden Valley (1 trial), Richfield (1 trial), and Saint Paul (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 16 new trials launched this month, 15 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children, and 2 are female-only. Academic institutions continue to play a vital role in Rochester's research ecosystem, with the Mayo Clinic sponsoring the majority of new studies (12 trials). Industry sponsors like Eli Lilly and Company (1 trial) are also driving significant research efforts.

As we move further into spring, Rochester's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.